Back to search

University of North Dakota

Determining Which Selective Serotonin Reuptake Inhibitor to Choose for the Treatment of Depression with Co-Morbid Conditions

Abstract

dc:description.abstract

Depression is one of the most prevalent disabling diseases affecting millions of people around the world. Many depressed individuals also suffer from co-morbid conditions that complicate treatment of their depression. Joe is a 65 year old male being seen for fatigue and a PHQ-9 score of 10. Initiation of treatment for depression was commenced with the serotonin reuptake inhibitor, sertraline. Selective serotonin reuptake inhibitors (SSRis) are first line medications for the treatment of depression. Pharmacological and clinical studies have identified slight differences in the profile of each SSRI, giving them unique advantages for use in comorbid conditions such as anxiety, obsessive compulsive disorder, obesity, insomnia, and cognitive deficits. Many of the SSRis have been found to be equally efficacious in the treatment of conditions, or conflicting results cannot discern an advantage of one SSRI over another. Sertraline has been found to be the most cost-effective SSRI in the treatment of depression, while escitalopram is the SSRI to be the best tolerated with the least likelihood of causing drug-drug interactions. Choosing the appropriate SSRI for the treatment of depression while considering co-morbid conditions can improve overall outcomes and compliance with the treatment plan

Degree

thesis:*
Name thesis:degree_name
Master of Science (MS)
Level thesis:degree_level
Independent Study

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Manderschied, Kristen

Identifiers

dc:identifier.*
Repository record dc:identifier
https://commons.und.edu/theses/5036

Chain of custody

source
Harvested from
University of North Dakota
Base URL
commons.und.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Manderschied, Kristen. Determining Which Selective Serotonin Reuptake Inhibitor to Choose for the Treatment of Depression with Co-Morbid Conditions. Independent Study thesis, https://commons.und.edu/theses/5036